A share price of Ginkgo Bioworks Holdings Inc [DNA] is currently trading at $9.66, down -5.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNA shares have gain 10.53% over the last week, with a monthly amount glided 21.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock has seen the most recent analyst activity on May 15, 2024, when BTIG Research downgraded its rating to a Sell. Previously, William Blair downgraded its rating to Underperform on May 10, 2024. On November 14, 2023, downgrade downgraded it’s rating to Mkt Perform and revised its price target to $2.50 on the stock. BTIG Research downgraded its rating to a Neutral. Goldman downgraded its rating to a Sell and reduced its price target to $1.25 on June 02, 2023. William Blair downgraded its rating to Mkt Perform for this stock on May 11, 2023. In a note dated November 29, 2022, Berenberg initiated an Buy rating and provided a target price of $6 on this stock.
Ginkgo Bioworks Holdings Inc experienced fluctuations in its stock price throughout the past year between $5.26 and $74.00. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Ginkgo Bioworks Holdings Inc [NYSE: DNA] shares were valued at $9.66 at the most recent close of the market. An investor can expect a potential drop of -27.54% based on the average DNA price forecast.
Analyzing the DNA fundamentals
Trailing Twelve Months sales for Ginkgo Bioworks Holdings Inc [NYSE:DNA] were 217.95M which represents 60.65% growth. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -2.71%, Pretax Profit Margin comes in at -2.99%, and Net Profit Margin reading is -2.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.7 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.31 points at the first support level, and at 8.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.19, and for the 2nd resistance point, it is at 10.72.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ginkgo Bioworks Holdings Inc [NYSE:DNA] is 5.79. On the other hand, the Quick Ratio is 5.79, and the Cash Ratio is 5.39. Considering the valuation of this stock, the price to sales ratio is 2.41, the price to book ratio is 0.61.
Transactions by insiders
Recent insider trading involved Che Austin, Officer, that happened on Dec 27 ’24 when 99.0 shares were purchased. Officer, Che Austin completed a deal on Dec 26 ’24 to buy 99.0 shares. Meanwhile, Officer Che Austin bought 99.0 shares on Dec 24 ’24.
